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Abstract
Background: Insulin-like Growth Factor-I (IGF-I) supplementation restores testicular atrophy
associated with advanced liver cirrhosis that is a condition of IGF-I deficiency. The aim of this work
was to evaluate the effect of IGF-I in rats with ischemia-induced testicular atrophy (AT) without
liver disease and consequently with normal serum level of IGF-I.
Methods: Testicular atrophy was induced by epinephrine (1, 2 mg/Kg intra-scrotal injection five
times per week) during 11 weeks. Then, rats with testicular atrophy (AT) were divided into two
groups (n = 10 each): untreated rats (AT) receiving saline sc, and AT+IGF, which were treated with
IGF-I (2 µg.100 g b.w.-1.day-1, sc.) for 28d. Healthy controls (CO, n = 10) were studied in parallel.
Animals were sacrificed on day 29th. Hypophyso-gonadal axis, IGF-I and IGFBPs levels, testicular
morphometry and histopathology, immuno-histochemical studies and antioxidant enzyme activity
phospholipid hydroperoxide glutathione peroxidase (PHGPx) were assessed.
Results: Compared to controls, AT rats displayed a reduction in testicular size and weight, with
histological testicular atrophy, decreased cellular proliferation and transferrin expression, and all of
these alterations were slightly improved by IGF-I at low doses. IGF-I therapy increased signifincantly
steroidogenesis and PHGPx activity (p < 0.05). Interestingly, plasma IGF-I did not augment in rats
with testicular atrophy treated with IGF-I, while IGFBP3 levels, that reduces IGF-I availability, was
increased in this group (p < 0.05).
Conclusion: In testicular atrophy by hypoxia, condition without IGF-I deficiency, IGF-treatment
induces only partial effects. These findings suggest that IGF-I therapy appears as an appropriate
treatment in hypogonadism only when this is associated to conditions of IGF-I deficiency (such as
Laron Syndrom or liver cirrhosis).
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Background
Insulin-Like Growth Factor-I (IGF-I) is an anabolic hor-
mone, produced mainly in the liver by GH stimulation
[1]. In advanced liver cirrhosis plasma levels of IGF-I are
reduced [1] because liver biosynthesis and GH receptor
expression in hepatocytes are decreased. Testicular atro-
phy is a common complication in advanced cirrhosis. Pre-
vious results have shown that IGF-I supplementation
recovers testicular atrophy associated to experimental cir-
rhosis [1]. Since advanced cirrhosis is a condition of "IGF-
I deficiency" and IGF-I therapy was able to revert testicular
atrophy in cirrhotic rats in only three weeks, a direct effect
of IGF-I on testes seems to be the most important factor to
explain our findings. This idea is supported by the exist-
ence of receptors for IGF-I in Sertoli cells, germ cells and
Leydig cells [2,3]. Following treatment with exogenous
IGF-I patients with Laron dwarfism, a condition of IGF-I
deficiency due to the absence of receptors for growth hor-
mone, show an increase in testicular size and serum testo-
sterone levels [4]. Stopping IGF-I administration led to a
return of both parameters to the pretreatment situation
indicating a specific effect of IGF-I [4].
On the other hand, since IGF-I therapy was also able to
improve nutritional status, intestinal absorption and liver
function tests [5-9], other factors could contribute to the
gonadal improvement observed in these rats with cirrho-
sis treated with IGF-I.
The aims of the present study were: 1) to go more into the
beneficial effects of the mechanisms mediated by IGF-I;
and 2) investigate if IGF-I therapy could be an adequate
treatment to improve testicular function in other condi-
tions without liver disorder and consequently with nor-
mal serum levels of IGF-I.
With these objectives, the present work was carried out
using an experimental model of hypoxia-induced testicu-
lar atrophy including three groups: healthy controls,
untreated rats with testicular atrophy and rats with testic-
ular atrophy treated with low doses of IGF-I during 28
days. Testes histopathology and function, pituitary-
gonadal axis and IGF-I and IGFBPs plasma levels were
assessed in the three experimental groups.
Methods
Induction of testicular atrophy
Testicular atrophy was induced as previously described
[10]. Briefly, male Wistar rats (4 weeks old, 150–160 g)
were subjected to 1.2 mg/Kg b.w. five times/week intra-
scrotal injections of epinephrine in sterile saline (Sigma),
for 11 weeks. Rats were housed in cages placed in a room
with 12-hour light-dark cycle and constant humidity and
temperature (20°C). Both, food (standard semipurified
diet for rodents; B.K. Universal, Sant Vicent del Horts,
Spain) and water were given ad libitum. Healthy age-
matched control rats were studied in parallel. All experi-
mental procedures were performed in conformity with
The Guiding Principles for Research Involving Animals.
Study design and IGF-I treatment
After testicular atrophy induction (after 11 weeks receiv-
ing epinephrine), rats with testicular atrophy were ran-
domly assigned to receive either vehicle (saline) (Group
AT, n = 10) or recombinant human IGF-I (Chiron) (2 µg
× 100 g bw-1xday -1 in two divided doses, subcutaneously)
(Group AT+IGF, n = 10) for four weeks. Control rats
(Group CO, n = 10) received saline during the same
period.
In the morning of day 0 (before treatment), animals were
weighted and blood samples were drawn from the retro-
ocular venous plexus from all rats with capillary tubes
(Marienfeld, Germany). Serum samples were stored at -
20°C until used for analytical purposes.
In the morning of the 29th day, rats were weighted, blood
was obtained again and processed as previously indicated
and animals were sacrificed by decapitation. After the
abdominal cavity was opened, the testes were dissected
and weighted. The testicular diameters (AP and LM) were
measured in testes previously fixed for histology, using a
precision calliper, Mituyoto® (± 0.05 mm).
Testicular histopathology and PCNA and transferrin 
immunohisto-chemistry
Bouin-fixed tissues were processed and sections (4 µm)
were stained with Haemotoxylin and Eosin and Masson's
trichrome. For histopathological evaluation of testes 30
seminiferous tubules from each rat of the three groups
were blindly evaluated by two observers and the arithme-
tic mean of the scores was taken as the final result. Trans-
versal sections of seminiferous tubuli were examined and
evaluation of histological changes was made using a light
projection microscope (Micro Promar Leitz GMBH, Wet-
zlar, Germany) at 100 × magnification. The following
parameters were studied: tubular diameter, quantitation
of the presence of the different types of cells in tubuli,
presence of peritubular fibrosis, and the number of prolif-
erating cells. For general purposes Haematoxilin & Eosin
and Masson's trichrome staining were used. Specific tech-
niques for other purposes are specified in the correspond-
ing paragraphs.
Tubular diameters were expressed in µm. Changes in
tubuli were classified into five categories (Category I:
highest damage to Category V: full normality). Category I:
presence of only Sertoli cells; Category II: Sertoli cells plus
spermatids, Category III: Sertoli cells, plus spermatides,
plus spermatocytes, Category IV: presence of all kinds ofBMC Urology 2006, 6:4 http://www.biomedcentral.com/1471-2490/6/4
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cells but showing some morphological alterations (i.e.:
severe vacuolization, aberrant cells). Category V: presence
of all kinds of cells without morphological alterations.
The presence of peritubular fibrosis was evaluated in Mas-
son's trichrome preparations according to the thickness of
the staining of collagen deposition surrounding tubuli.
Proliferating cells were identified by immunostaining of
proliferating cellular nuclear antigen (PCNA) using an
avidin-biotin peroxidase method [11] with retrieval of
antigen by means of microware irradiation. Specific anti
PCNA antibody (mouse anti-PCNA, clone PC 10, DAKO,
Denmark) biotinylated rabbit anti-mouse IgG (DAKO,
Denmark) were used and the avidin-biotin complex tech-
nique (ABC, DAKO kit) was performed. The bound anti-
bodies were visualized by means of 3,3'-
diaminobenzidine tetrahydrochloride (SIGMA Chemical
Company, St. Louis, MO) with nickel enhancement (Shu
et al., 1988) [11]. Finally, samples were slightly counter-
stained (10 seconds) in hematoxilin, dehydrated, and
mounted in DPX. Controls were performed by substitu-
tion of the primary antibody by TBS. The number of
PCNA positive cells was recorded. The result was
expressed as stained cells per tubuli (arithmetic mean of
30 screened tubuli).
Taking into account all the parameters specified above, an
overall score of testicular histopathological damage was
adopted according to the following guidelines: Tubular
diameter (in µm) scored from 0 to 3 points: > 260 = 0
points; from 240 to 259 = 1 point; from 220 to 239 = 2
points; and < 219 = 3 points. Cellular counts in tubuli:
Category I (8 points), category II (6 points), category III (4
points), category IV (2 points) and category V (0 points).
The score was obtained by multiplying the number of
tubuli in each category by its respective points divided by
30 (the number of tubuli evaluated in each animal). Per-
Table 2: Parameters of testicular size and weight in the three experimental groups (day 29th).
Healthy Control rats (CO, n = 
10)
Untreated AT rats (CI, n = 10) AT rats treated with IGF-I 
(CI+IGF, n = 10)
Left teste weight·bw-1 3.87·10-3 ± 1.28·10-4 2.75·10-3 ± 2.35·10-4 *** 3.06·10-3 ± 2.31·10-4φ
External Testicular Diameters (mm):
• Longitudinal 16.05 ± 0.20 12.58 ± 0.22 *** 14.47 ± 0.30 ** &&
• Transversal 7.20 ± 0.17 4.98 ± 0.37 *** 5.69 ± 0.22 **&&
m ± SEM; *p < 0.05 vs CO; **p < 0.01 vs CO; ***p < 0.001 vs CO; φ p < 0.07 AT vs AT+IGF; &&p < 0.01 AT vs AT+IGF; &p < 0.05 AT vs AT+IGF
Table 1: Bioch emical data before and after IGF-I treatment (at low doses) in the three experimental groups.
Parameters Control rats 
(CO, n = 10)
Untreated AT rats 
(AT, n = 10)
AT rats treated with IGF-I 
(AT+IGF, n = 10)
Albumin (g/dL) Before 3.96 ± 0.16 3.60 ± 0.30 3.54 ± 0.30
After 4.16 ± 0.24 4.04 ± 0.17 4.11 ± 0.27
Cholesterol (mg/dL) Before 63 ± 6 64 ± 13 62 ± 12
After 55 ± 9 54 ± 7 52 ± 7
Creatinine (mg/dL) Before 0.61 ± 0.07 0.61 ± 0.06 0.68 ± 0.20
After 0.79 ± 0.15 0.79 ± 0.08 0.71 ± 0.11
Alkaline phosphatase (UI/L) Before 108 ± 22 127 ± 31 97 ± 27
After 75 ± 15 84 ± 12 69 ± 14
Glucose (mmol/dL) Before 9.3 ± 1.1 7.9 ± 1.9 9.0 ± 1.4
After 11.1 ± 1.2 8.6 ± 0.8 8.2 ± 1.1
Total protein (g/dL) Before 7.06 ± 0.29 6.32 ± 0.46 6.54 ± 0.61
After 7.17 ± 0.31 6.90 ± 0.37 7.04 ± 0.42
Urea (mg/dL) Before 35.6 ± 4.3 51.5 ± 7.2 48.1 ± 8.5
After 37.4 ± 2.9 49.9 ± 9.0 41.2 ± 5.3
m ± SEM; n = 10, p = nsBMC Urology 2006, 6:4 http://www.biomedcentral.com/1471-2490/6/4
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itubular fibrosis was scored from 0 (absent or minimal) to
1 (evident). Cellular proliferation (PCNA) was scored
from 0 to 3 according to the following criteria: when the
number of PCNA positive cells /tubule was higher than
60, the score was 0 point. When the number of PCNA pos-
itive cells / tubuli was lower than 60, the score was
obtained according to the following formula: (60 – PCNA
positive cells) × 0.05. Therefore the overall score of his-
topathological damage ranged from 0 (complete normal-
ity) to 15 (full abnormality).
In addition, the expression of transferrin in tubuli was
evaluated by immunostaining using similar technique as
for PCNA with specific anti-transferrin antibody
(obtained from rabbit, RARa/TRf, Nordic Immunological
Laboratories, Teknovas, The Netherlands). Transferrin
expression was scored from 0 to 4 points. If 30 tubuli
expressed transferrin normally all over the germinal epi-
thelium: 0 points. The remaining scores were obtained
according to the following formula: (30 - Tubuli showing
expression of transferrin all over the germinal epithelium) ×
0.075.
Analytical methods
Serum levels of albumin, total proteins, glucose, choles-
terol and alkaline phosphatase, were determined by rou-
Microscopy of testes (× 100 magnification, Masson's stain) Figure 2
Microscopy of testes (× 100 magnification, Masson's stain). 
Testicular histological section of normal rat (CO) demon-
strating active spermatogenesis in normal-size seminiferous 
tubuli with thin basement membranes and minimal peritubu-
lar fibrosis. Leydig cells are scarce, being widely separated by 
seminiferous tubuli. Seminiferous tubuli in testes from 
untreated animals with testicular atrophy (AT) appear seri-
ously damaged. These animals show a decrease of tubular 
diameter, vacuolization in germinal epithelium, lost of germi-
nal line, total reduction of spermatogenesis. AT rats treated 
with IGF-I (AT+IGF) show a significant improvement of all 
these alterations, although partial.
Macroscopic appearance of testes from healthy controls  (CO), untreated rats with testicular atrophy (AT) and rats  with testicular atrophy treated with IGF-I (AT+IGF) Figure 1
Macroscopic appearance of testes from healthy controls 
(CO), untreated rats with testicular atrophy (AT) and rats 
with testicular atrophy treated with IGF-I (AT+IGF). Note 
reduced volume of testes in AT rats.BMC Urology 2006, 6:4 http://www.biomedcentral.com/1471-2490/6/4
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tine laboratory methods using a Hitachi 747 autoanalyzer
(Boerhringer-Mannheim, Germany).
Serum levels of the different hormones were assessed by
RIA in a GammaChen 9612 Plus (Serono Diagnostics,
Roma, Italy) using specific commercial assay systems. The
sensitivity (S) of total Testosterone assay was 4 ng/dL and
the intraassay coefficient of variation (CV) was less than
7%. The sensitivity of free Testosterone assay was 0.15 pg/
mL and the CV was <8%. The sensitivity of Estradiol was
7 pg/mL and the CV was <7% (Coat-a-Count, DPC (Diag-
nostic Products Corporation, Los Angeles, CA). The kits
for Rat luteinizing Hormone (rLH) (S = 1.7 ng/mL and
CV<10%) and Rat follicle stimulating hormone (rFSH) (S
= 1.8 ng/mL and CV<6%) were provided from Amersham
International plc (Little Chalfont Buckinghamshire, Eng-
land HP7 9NA). Assessment of IGF-I was carried out after
an alcohol extraction in order to eliminate IGFBPs
(Nichols Institute Diagnostics, San Juan Capistrano, CA,
USA). The sensitivity of this assay was 21 ng/mL and the
intraassay coefficient of variation was less than 4%.
Antioxidant enzyme activity phospholipid hydroperoxide
glutathione peroxidase was determined as previosuly
reported [12]. Briefly, PHGPx catalizes the oxidation of
reduced glutathione (GSH) by phospholipids hydroper-
oxide in presence of glutathione reductase and NADPH.
Oxidized glutathione (GSSG) is immediately reduced to
GSH with the oxidation of NADPH to NADP+. And the
decrease of NADPH absorbance at 340 nm is assessed
using a Cobas Mira autoanalyzer (ABXMicro, Germany).
Finally, a unit of PHGPx was expressed as the amount of
enzime required to oxide 1 µmol/min of NADPH at 37°C
subtracting the blank of the reactives (S = 3.7 IU/L and
CV<10%).
Western-ligand blot
IGF binding proteins (IGFBPs) were studied using West-
ern blot analysis which was performed as described by
Hossenlopp et al [13] and Hardouin et al. [14]. Briefly, rat
plasma (3 µL) was diluted up to 50 µL in 0.06 M Tris-HCl
and 0.15 M NaCl, pH 6.8, with 5% SDS, 20% glycerol and
0.02% bromophenol blue. The solution was submitted to
a 5–15% gradient SDS-PAGE. Proteins were blotted to a
0.2 µm nitrocellulose filter (Bio-Rad). Nitrocellulose filter
was dried for 5 min at 37°C, followed by quenching firstly
in Tris buffer alone, and then in Tris buffer with 3% NP-
40 (30 min at 4°C). Finally, the filter was soaked in Tris
buffer with 1% BSA and 0.1% Tween-20 for 60 min, and
was then incubated over-night with 200000 cpm 125I-IGF-
Table 4: The pituitary-gonadal axis (on day 29th) in the three experimental groups.
Healthy Control rats (CO, n = 
10)
Untreated rats with testicular 
atrophy (AT, n = 10)
IGF-I-treated AT rats 
(AT+IGF, n = 10)
Total Testosterone (ng/dL) 88.10 ± 23.66 59.68 ± 19.70* 71.17 ± 15.86#
Free Testosterone (pg/mL) 7.35 ± 2.91 0.84 ± 0.67*** 2.88 ± 1.45** &
Estradiol (pg/mL) 8.20 ± 1.84 9.86 ± 3.35 9.93 ± 1.37
Estradiol/Total Testosterone 10.33 ± 7.11 61.47 ± 10.77 17.78 ± 13.92
LH (ng/mL) 2.16 ± 0.15 2.73 ± 0.36 3.28 ± 0.51*
FSH (ng/mL) 12.86 ± 1.20 17.80 ± 0.82* 20.58 ± 1.13** &
m ± SEM; *p < 0.05, **p < 0.01, ***p < 0.001 CO vs other groups; &p < 0.05 AT vs AT+IGF; #p = 0.06 AT vs AT+IGF
Table 3: Cellular analysis: 30 seminiferous tubuli were examined in each preparation. The table summarizes the number of tubuli in 
each category: category I = only Sertoli's cells; category II = I+espermatids; category III = II+espermatocytes; category IV= all types of 
cell but with some alterations; category V= all types of cells with normal features.
Category I
(number of tubules)
II
(number of tubules)
III
(number of tubules)
IV
(number of tubules)
V
(number of tubules)
Controls (CO) 
(n = 10) × 30 tubuli
000 1 5 2 8 5
Rats with testicular atrophy 
(AT) (n = 10) × 30 tubuli
120 62 44 12 62
IGF-treated AT rats 
(AT+IGF) 
(n = 10) × 30 tubuli
25 25 56 81 113
Statistical analysis p < 0.001 AT vs 
other groups
p < 0.001 AT vs 
CO p < 0.01 AT vs 
AT+IGF
p < 0.05 AT vs CO 
and AT+IGF vs CO
p < 0.001 AT+IGF 
vs CO and AT+IGF 
vs AT
p < 0.01 AT vs CO 
p < 0.05 AT vs 
AT+IGF p < 0.05 
AT+IGF vs COBMC Urology 2006, 6:4 http://www.biomedcentral.com/1471-2490/6/4
Page 6 of 10
(page number not for citation purposes)
I. After washing several times with buffer, the filter was
dried and, lastly, exposed to an autoradiographic film.
Densitographic quantitation of IGFBPs was expressed in
arbitrary units of optic density (mm2)
Statistical analysis
Data are expressed as mean (± SEM). To assess the homo-
geneity among the three groups of rats a Kruskall-Wallis
test was used, followed by multiple post-hoc comparisons
using the Mann-Whitney U test (two tailed) with Bonfer-
roni adjustment. A regression model was fitted consider-
ing histopathological score, PCNA or transferrin
expression scores and IGF-I plasma concentration as the
dependent and independent variables respectively.
Within groups differences between pre- and post-treat-
ment values were assessed by means of Wilcoxon matched
pairs signed rank sum test. Any p value less than 0.05 was
considered to be statistically significant. Calculations were
performed with SPSSWin v.6.0. Program.
Results
At baseline, both groups with testicular atrophy showed
similar serum levels of albumin, cholesterol, creatinine,
alkaline phosphatase, glucose, total proteins and urea,
which were all normal as compared with control rats
(Table 1).
Testicular morphology and morphometry
There was a reduction in testicular size and volume in
group AT as compared with control (Figure 1). Morpho-
metric study showed a significant reduction in testicular
weight (more expressive when values were corrected by
body weight) in group AT compared to controls and
AT+IGF group. Noteworthy, no significant differences
were found between AT+IGF and controls. Longitudinal
and transversal testicular diameters were reduced in AT
group and increased significantly in rats treated with IGF-
I (AT+IGF). Morphometric data in the three groups are
summarized in Table 2.
Testicular histopathology
In AT group histological examination revealed testicular
atrophy with marked decrease in tubular diameter
expressed as an index of damage scored from 0 to 3 points
(see Methods) (CO: 0.25 ± 0.05; AT: 2.07 ± 0.19, p <
0.001). IGF-I therapy induced a significant improvement
of this parameter (1.45 ± 0.18, p < 0.05 vs group AT and p
< 0.01 vs controls). Histopathological findings in
untreated AT rats included: vacuolization of Sertoli's cells,
loss of germinal line, detached germ cells, dramatic reduc-
tion of spermatogenesis, presence of abnormal sperma-
tids or empty tubulli, and peritubular fibrosis. These
alterations were much less intense or almost absent in rats
receiving IGF-I (see Figure 2 for morphological compari-
son among groups). These changes are presented in Table
3 according to a pre-established score (see Methods), after
exploring 30 tubuli from each preparation.
Testicular cellular proliferation, as evaluated by PCNA
positive cells, was significantly reduced in both groups
with testicular atrophy: IGF-I therapy induced an
improvement but it did not reach statistical significance
(mean of PCNA + cells scored in 30 tubuli for each ani-
mal; CO: 63.8 ± 1; AT: 36 ± 8, p < 0.001 AT vs CO;
AT+IGF: 47 ± 5, p < 0.05 CO vs AT+IGF). Figure 3 shows
PCNA immuno-histochemistry in the three groups.
Study of proliferative activity, assessed by PCNA immunos- taining Figure 3
Study of proliferative activity, assessed by PCNA immunos-
taining. Reduced or absent cellular proliferation in untreated 
animals with testicular atrophy (AT) and a recovered germi-
nal line in IGF-I-treated AT rats (AT+IGF) can be observed.BMC Urology 2006, 6:4 http://www.biomedcentral.com/1471-2490/6/4
Page 7 of 10
(page number not for citation purposes)
Taking together all the morphological data a score of his-
topathological testicular damage was established (see
Methods). The values of histopathological score were:
CO: 0.49 ± 0.14; AT: 12.44 ± 1.29 (p < 0.001 AT vs CO);
and AT+IGF: 7.78 ± 1.38 (p < 0.001 vs CO and p < 0.01 vs
AT), demonstrating severe testicular damage in untreated
AT rats and a significant improvement in AT rats treated
with IGF-I.
Testicular transferrin, a marker of the integrity of the
hemato-testicular barrier and Sertoli cell function, was
evaluated from 0 to 4 points by immunohistochemistry in
testicular slices (see Methods). Transferrin expression was
decreased in AT rats (1.83 ± 0.43 points, p < 0.001 vs
groups CO and AT+IGF) as compared with controls (3.85
± 0.15 points) and to rats with testicular atrophy receiving
IGF-I (2.60 ± 0.30 points, p < 0.001 vs groups CO and
AT+IGF). A close inverse correlation was found between
testicular transferrin expression and histopathological tes-
ticular damage score (r = -0.85, p < 0.001).
Pituitary-gonadal axis
Untreated AT rats showed a significant reduction of serum
levels of both total (p < 0.05) and free testosterone (p <
0.001) with increases of LH and FSH (p < 0.05) levels as
well as the estradiol/testosterone ratio. However, in the
group of rats with testicular atrophy treated for four weeks
with low doses of IGF-I, a partial recovery was observed
with an increase of the levels of both free (p < 0.05 vs
untreated group) and total testosterone (p = 0.06 vs
untreated group) and a significant reduction of the estra-
diol/total testosterone ratio (Table 4).
Another interesting result was that comparing data from
before and after treatment testosterone concentrations
were increased (p < 0.05 before and after treatment) in all
animals treated with IGF-I (Figure 4).
Serum levels of IGF-I and IGFBPs expression
At the time of sacrifice (day 29th), 14–16 hours after the
last IGF-I injection, surprisingly serum levels of IGF-I did
not increase in rats with testicular atrophy treated with
IGF-I (AT+IGF) (CO: 2257 ± 183 ng/ml; AT: 2209 ± 91 ng/
ml; AT+IGF-I: 1910 ± 76 ng/ml).
The main IGFBPs were determined by Western-ligand-
blot, showing changes in the pattern of IGFBPs with a sig-
nificant increment of IGFBP3 in rats with testicular atro-
phy treated with IGF-I (Arbitrary Units, CO: 23.77 ± 0.48,
AT: 23.01 ± 0.95, AT+IGF: 28.24 ± 1.11) (see Figure 5). An
increase of IGFBP 1 and 2 (AU, CO: 3.31 ± 0.68; AT: 2.90
± 0.78; AT+IGF: 6.47 ± 1.74) was also observed but it did
not reach statistical significance.
PHGPx activity in testicular homogenates
The values of PHGPx, an antioxidant enzyme, showed a
significant increase in the AT+IGF group with regard to
untreated animals with testicular atrophy (CO: 6 ± 0.2 IU/
mg of protein; AT: 5 ± 0.3 IU/mg of protein; AT+IGF: 8 ±
0.7 IU/mg of protein), showing an antioxidant effect of
IGF-I therapy on testes.
Testosterone levels before and after IGF-treatment in rats  with testicular atrophy (AT+IGF) (p < 0.05) Figure 4
Testosterone levels before and after IGF-treatment in rats 
with testicular atrophy (AT+IGF) (p < 0.05).
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Discussion
Insulin-like growth factor-I reverted testicular atrophy in
rats with advanced cirrhosis, condition with "IGF-I defi-
ciency" [1]. A question arises as to whether the beneficial
effects of IGF-I on testicular atrophy are derived from the
direct action of IGF-I or these effects are an epiphenome-
non secondary to the general improvement induced by
IGF-I in cirrhotic animals [1,5-8]. The direct action of IGF-
I would allow us to suggest this therapy for other condi-
tions with testicular damage.
In order to clarify this point, we employed another exper-
imental model with a testicular atrophy and gonadal
insufficiency induced by local ischemia for investigating
the effect of IGF-I on testes in animals with neither hepatic
disease nor malnutrition. However, testicular damages
caused in this model were more severe than those found
associated to advanced liver cirrhosis.
The animals included in the present study were shown to
display a dramatic testicular damage manifested by a vari-
ety of histopathological abnormalities which include a
reduction of testicular size, congestion and severe edema,
alterations in tubular diameters, complete loss of the ger-
minal line and total reduction of cellular proliferation as
it has been previously reported [15-17]. These alterations
could resemble in human pathology only those found in
untreated testicular torsion [18].
In this assay, IGF-I treatment (at low doses) induced a lit-
tle and partial improvement of testicular histology,
increasing cellular proliferation and transferrin expres-
sion. In addition, IGF-I therapy increased serum testoster-
one levels (p < 0.05) (see Figure 4). The found results
evidence a direct effect of IGF-I on testes but more inter-
estingly show the difficulty to increase IGF-I serum levels
and its availability using the reported low doses. These
low doses were chosen in order to avoid hypoglucemia
and other side effects.
Consistent with these findings, it has been reported that
IGF-I exerts potent trophic and hormonogenetic effects on
testis [1] and it is a critical autocrine and/or paracrine fac-
tor in the control of adult Leydig cells numbers and func-
tion and luteinizing hormone acts in part through IGF-I to
stimulate proliferative activity [19]. The absence of IGF-I
secretion in male GHR-KO mice is associated with a
decreased plasma testosterone response to LH treatment
and with a reduction in the number of testicular LH recep-
tors [20].
In mouse, IGF-I gene null homozygous mutation led to a
reduced testicular size, decrease of testosterone produc-
tion and infertility [21]. It has also been reported that
FSH-induced aromatization of androgens to estrogens in
rat Sertoli cells in culture is markedly inhibited by IGF-I
treatment through the reduction of aromatase mRNA
[22]. Of interest, the recovery of transferrin expression in
Sertoli cells observed in our study suggests a role of IGF-I
in maintaining the integrity of the hematotesticular bar-
rier [23] and consequently on cellular proliferation in
some tubuli. Transferrin expresion by Sertoli cells is con-
sidered as a good marker of the testicular barrier integrity.
This beneficial effect of IGF-I is in agreement with previ-
ous findings in animals with liver cirrhosis [1,24]. Since
Sertoli cell factors influence on the Leydig cell function
the improvement induced by IGF-I therapy on Sertoli cell
may explain, at least partially, the found increase of testo-
sterone.
Systemic IGF-I plays a major modulatory role in testicular
endocrine function [20]. Interestingly, in the present work
plasma levels of IGF-I did not increase in rats with testic-
ular atrophy treated with IGF-I. Since the half-life for IGF-
I is estimated in 14–22 hours [24,25], we propose that the
hormone could be proteolyzed [26]. Similar findings have
been observed administrating these low doses of IGF-I to
animals with normal liver function. IGF-I is degraded
within the endosomal apparatus as a consequence of
receptor-mediated endocytosis [26]. These molecular
mechanisms could be involved in the close regulation of
circulating levels of IGF-I. Futher aditional studies could
be necesary to understand better IGF-I regulation.
In addition, the availability of administered IGF-I seems
to be reduced in this study since IGFBP-3 expression is
increased after the IGF-I treatment (see Figure 5). Thus the
exogenous supplementation of IGF-I induces an increase
in the IGFBP-3 expression, which reduces the bioavailabil-
ity of the administered hormone [24]. The ratio IGF-I/
IGFBP3 is considered a marker of the IGF-I bioavailability
[14,24], and normal spermatogenesis and perhaps also
steroidogenesis are dependent on the actions of sufficient
concentrations of unbound IGF-I [21,23,27,28].
The explanation for these results could be that this exper-
imental model (testicular atrophy by hypoxia) is not an
"IGF-I deficiency" condition. In this work IGF-I therapy
induces some but little effects on testes, because the mech-
anisms of control of this hormone are closely regulated.
The excess of IGF-I is down-regulated by the increase in
IGFBP-3 and probably by the proteolytic metabolism of
this hormone, because IGF-I plasma levels are not
increased in IGF-I treated animals. These results suggest
that the unique therapeutical possibility of IGF-I adminis-
tration seem to be in conditions "with IGF-I deficiency"
(as it is common with other hormones) although it is pos-
sible to see a direct action of IGF-I on testes in all condi-
tions.BMC Urology 2006, 6:4 http://www.biomedcentral.com/1471-2490/6/4
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Conclusion
In conclusion, the therapy with IGF-I is effective only in
conditions of IGF-I deficiency, recovering testicular atro-
phy as it has been shown in advanced cirrhosis [1,23] or
in Laron Syndrome [4]. In conditions of testicular damage
where there is no IGF-I deficiency the exogenous adminis-
tration of this hormone is buffered inducing only a little
improvement on testicular histology and function.
The reported results in this work allow us to rule out the
IGF-I supplementation as a therapeutic strategy in condi-
tions without "IGF-I deficiency".
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